The thesis

AKTS is a clinical-stage biotechnology firm developing radiopharmaceutical therapies with a gross margin of 8721.0%. The company's conviction tier is 33/100, indicating low conviction. Analyst consensus rating is BUY, despite a P/E of -36.7x and net margin of -65652.0%. This discrepancy makes the setup interesting,

Why now

The current macro context, with China's chip tool push and the US-China squeeze, may impact AKTS's ability to secure funding. The company's low conviction tier and negative valuation metrics make it a high-risk investment,

What to watch

The company's future financial reports, particularly the net margin and P/E ratio, will be crucial in confirming or denying the thesis. The outcome of AKTS's clinical trials and the impact of the US-China trade tensions on the biotechnology sector will also be important indicators to watch over the next quarter

Key risks

Valuation risk is a major concern due to AKTS's negative P/E and net margin. Execution risk is also a factor, as the company's clinical-stage development may not yield expected results. Competitive risk from established players in the radiopharmaceutical market is another threat,